Optima Health PLC

The company's capital structure is characterized by a low debt-to-equity ratio of 0.13, indicating a conservative leverage position. However, the free cash flow is negative at -12.43 million GBP, which may signal reinvestment in the business or operational inefficiencies. The current ratio of 2.68 suggests strong short-term liquidity, but the negative net cash position after subtracting total debt raises concerns about the company's ability to meet long-term obligations.

Profitability metrics show a return on equity (ROE) of 0.98% and a return on assets (ROA) of 0.76%, both of which are relatively low. These figures suggest that the company is not generating substantial returns relative to its equity and asset base. The operating margin, calculated as operating income divided by revenue, is 3.09%, which is below the industry median for healthcare facilities and services. This indicates that the company may be facing cost pressures or pricing challenges.

Geographically, the company's revenue is concentrated in the United Kingdom, as disclosed in its financial statements. There is no significant diversification across regions, which could expose the company to local economic or regulatory risks. The company does not report segment-specific revenue, making it difficult to assess the performance of individual business lines.

The company's growth trajectory is mixed. While the current fiscal year shows a revenue of 105.05 million GBP, the outlook for the next fiscal year is not explicitly provided. The negative free cash flow and low profitability suggest that the company may be investing heavily in growth initiatives or facing operational headwinds. The capital expenditure of -3.75 million GBP indicates ongoing investment in infrastructure or expansion.

Risk factors include medium liquidity risk, as highlighted by the negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted figures. However, the company's reliance on a single geographic market and the absence of segment-specific data increase the uncertainty around its long-term sustainability.

Recent events include analyst estimates indicating a mean price target of 248.39 GBP and a median price target of 251.71 GBP. The mean recommendation of 1.33 suggests a generally positive outlook from analysts, with two strong-buy ratings and one buy rating. No hold or sell ratings were reported, indicating a consensus for growth.